Brain-derived neurotrophic factor Val66Met polymorphism is associated with mild cognitive impairment in elderly patients
- PDF / 720,372 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 71 Downloads / 179 Views
ORIGINAL ARTICLE
Brain‑derived neurotrophic factor Val66Met polymorphism is associated with mild cognitive impairment in elderly patients with type 2 diabetes: a case‑controlled study Jia Liu1 · Wei Yang1 · Hongyu Luo1 · Yixin Ma1 · Huan Zhao1 · Xiaojuan Dan2 Received: 11 March 2020 / Accepted: 17 August 2020 © Springer Nature Switzerland AG 2020
Abstract Background Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is reported to be associated with cognitive dysfunction, an important comorbidity factor in patients with type 2 diabetes mellitus (T2DM), especially in elderly populations, however, the underlying pathophysiological mechanisms are unclear. Aim This study was performed to investigate the association between BDNF Val66Met polymorphism and mild cognitive impairment (MCI) in elderly patients with T2DM. Methods In total, 105 MCI and 105 normal cognition controls of T2DM patients were enrolled; all of the patients underwent neuropsychological assessments. BDNF Val66Met polymorphism was genotyped via TaqMan SNP genotyping assay. Data from clinical and laboratory-based examinations were collected. Results The frequency of the BDNF Met allele was significantly higher in the MCI group than in the controls. Multiple regression analysis indicated an association of the Met allele with MCI in patients with T2DM (OR = 2.54; 95% CI 1.33–4.84; p = 0.005). Stratified by educational level, the BDNF Met allele was significantly associated with MCI in elderly T2DM patients (OR = 3.29; 95% CI 1.26–8.57; p = 0.015) among the group of low educational levels ( A) is located in the coding exon of the BDNF gene; it is a missense mutation that leads to an amino acid substitution (valine converts to methionine), which affects the secretion of BDNF [14]. Healthy individuals carrying the BDNF Met showed decreased hippocampal volume and hippocampal associated memory, which may be related to the onset of AD and MCI [15, 16]. Although BDNF Val66Met polymorphism may not contribute directly to T2DM susceptibility, BDNF-Met carriers were recently reported to have a lower delayed memory index score compared with T2DM patients who were Val carriers [12]. Nevertheless, the association between BDNF Val66Met polymorphism and MCI in patients with diabetes has not yet been explored, especially in elderly populations. Additionally, some related factors, such as age, T2DM duration, glucose fluctuation, hypoglycemic or hyperglycemic events and vascular complications are associated with cognitive impairment in T2DM patients. However, but some data suggest that the anti-diabetic drugs, such as dipeptidly1 peptidase-4 inhibitor (DPP4i) or glucagon-like peptide 1 (GLP-1) receptor agonist, may help prevent cognitive decline in elderly patients with T2DM [17, 18]. Increased plasma DPP4 activity and reduced BDNF level in peripheral circulation are involved in the pathogenesis of MCI in T2DM [19]. DPP4-i has been shown neuroprotective effects that could be partially mediated through the effect of GLP-1 in the brain and contribute to the
Data Loading...
